目的:分析腓骨肌萎缩症（CMT）常用量表的相关性，探讨四种常见CMT基因亚型（CMT1A、CMT1X、CMT2A和MPZ相关CMT）在首诊横断面的神经功能障碍特点。方法:纳入2009—2019年期间就诊于中南大学湘雅三医院神经内科、已明确基因诊断且首诊年龄≥10岁的CMT患者共117例，其中CMT1A型45例、CMT1X型41例、CMT2A型19例、髓鞘蛋白零（MPZ）相关CMT 12例。系统收集所有患者首诊时的临床资料并进行腓骨肌萎缩症神经病变评分（CMTNS）、腓骨肌萎缩症检查评分（CMTES）、总体神经功能限制评分（ONLS）和功能残疾评分（FDS），采用Spearman检验分析CMTES、ONLS、FDS与CMTNS的相关性；分析四组基因亚型患者组间及组内性别、发病年龄、病程、量表评分等临床特点。结果:117例CMT首诊患者的男女比例为1.79∶1，发病年龄为（19±13）岁，病程为10（3，15）年，首诊时CMTNS为（11.4±6.2）分，CMTES为（8.8±5.7）分，ONLS为（2.7±1.4）分，FDS为（2.6±1.3）分。CMTES、ONLS、FDS评分与CMTNS评分在117例CMT患者及其四个基因型亚组中均呈正相关（均n r≥0.40，n P<0.05）；CMTNS、CMTES、ONLS评分均显示与各基因亚型病程呈正相关（均n P0.05）。CMT2A患者发病年龄早于CMT1A、CMT1X及MPZ相关的CMT（n P<0.05），且早发型CMT2A患者的各量表评分高于成年型CMT2A患者：CMTNS、CMTES、ONLS、FDS（均n P<0.05）；CMT1X男性患者的各量表评分均高于女性CMT1X患者：CMTNS、CMTES、ONLS、FDS（均n P<0.05）。n 结论:CMTNS、CMTES与ONLS评分可用于CMT各基因亚型的自然病史和临床试验等研究。CMT2A患者发病年龄较早，早发型CMT2A患者较成年型的功能障碍严重。CMT1X男性患者的神经功能障碍较女性患者重。“,”Objective:To analyze the correlations among different common scales for evaluating the severity of the first-visit Charcot-Marie-Tooth disease (CMT), and explore the cross-sectional characteristics of neurological dysfunction in patients with four common genotypes (CMT1A, CMT1X, CMT2A and MPZ-related CMT) at their first visits.Methods:A total of 117 genetically confirmed CMT patients (aged ≥10 years) from the Department of Neurology of the Third Xiangya Hospital from 2009 to 2019 were included in the study, which consisted of 45 CMT1A, 41 CMT1X, 19 CMT2A, and 12 MPZ-related CMT patients. Clinical data of these patients at first visits were collected and neurological deficits were evaluated by Charcot-Marie-Tooth Neuropathy Score (CMTNS), Charcot-Marie-Tooth Examination Score (CMTES), Overall Neuropathy Limitation Scale (ONLS) and Functional Disability Scale (FDS). Spearman′s correlation was performed to analyze the relationship between CMTNS, CMTES, ONLS and FDS. The age of onset, duration of disease, scores of CMTNS, CMTES, ONLS and FDS were compared among four genotypes.Results:In the 117 CMT patients, the male to female ratio was 1.79/1, and the age of onset was (19±13) years. The duration of disease was 10(3, 15) years, and the scores of CMTNS, CMTES, ONLS and FDS were 11.4±6.2, 8.8±5.7, 2.7±1.4 and 2.6±1.3, respectively. There was a significant correlation between CMTES, ONLS, FDS and CMTNS in the overall CMT patients and four subtypes respectively (n r≥0.40, n P<0.05). CMTNS, CMTES and ONLS scores of four subtypes showed positive correlations with duration of disease (n P0.05) at their first visits. The age of onset in CMT2A patients was younger than that of the patients with the other three genotypes (n P<0.05), furthermore, the scores of four scales in early-onset CMT2A patients were higher than those of adult-onset type CMT2A patients (CMTNS:n P=0.031, CMTES: n P=0.048, ONLS: n P=0.042, FDS: n P=0.047). In CMT1X patients, the males had higher scores than those of females for all four scales (CMTNS: n P=0.028, CMTES: n P=0.014, ONLS: n P=0.023, FDS: n P=0.002).n Conclusions:CMTNS, CMTES and ONLS could be used in natural history studies and clinical trials according to the different clinical situations. In the four genotypes, CMT2A patients have younger age of onset, and the earlier the age of onset, the severer the dysfunction. Moreover, male CMT1X patients relatively have severer neurological dysfunction than female patients.